Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Joanna Kryst"'
Autor:
Olga Czerwińska-Ledwig, Małgorzata Żychowska, Artur Jurczyszyn, Joanna Kryst, Jakub Deląg, Andżelika Borkowska, Joanna Reczkowicz, Tomasz Pałka, Przemysław Bujas, Anna Piotrowska
Publikováno v:
Journal of Clinical Medicine, Vol 13, Iss 10, p 2771 (2024)
Background: Multiple myeloma (MM) accounts for about 10–15% of all diagnosed hematologic malignancies and about 1–2% of all cancer cases. Approximately 80–90% of MM patients develop bone disease and the changes rarely regress. It is only possib
Externí odkaz:
https://doaj.org/article/b0fcc2865a414147b1782fdf804974d0
Autor:
Olga Czerwińska-Ledwig, Joanna Kryst, Ewa Ziemann, Andżelika Borkowska, Joanna Reczkowicz, Adrianna Dzidek, Łukasz Rydzik, Tomasz Pałka, Małgorzata Żychowska, Wojciech Kupczak, Marta Mydlárová Blaščáková, Anna Piotrowska
Publikováno v:
Nutrients, Vol 16, Iss 10, p 1413 (2024)
The aim of the study was to assess the impact of two lengths of Nordic walking (NW) training interventions combined with time-restricted eating (TRE) on improving body-composition parameters, lipid profiles, and levels of selected adipokines in women
Externí odkaz:
https://doaj.org/article/ab503fac1d554b0baa319920a24deb96
Publikováno v:
PLoS ONE, Vol 10, Iss 5, p e0124279 (2015)
Efavirenz, a non-nucleoside reverse-transcriptase inhibitor (NNRTI) is one of the most commonly prescribed antiretroviral drugs. The present article provides a systematic overview and meta-analysis of clinical trials comparing efavirenz and other act
Externí odkaz:
https://doaj.org/article/4fdda77b582d439180a7773d8340dabf
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e76587 (2013)
BACKGROUND:Nevirapine belongs to the group of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and is commonly administered in first-line treatment of HIV infection. OBJECTIVE:Systematic review and meta-analysis was undertaken to compare effe
Externí odkaz:
https://doaj.org/article/52ea759293a1480aaf69af11bff27e5d
Publikováno v:
Pharmacological Reports. 75:293-319
Background Early-life stress (ELS) affects brain development and increases the risk of mental disorders associated with the dysfunction of the medial prefrontal cortex (mPFC). The mechanisms of ELS action are not well understood. Endoplasmic reticulu
Publikováno v:
Pharmacological Reports. 74:920-946
Background Drugs prescribed for psychiatric disorders in adolescence should be studied very extensively since they can affect developing and thus highly plastic brain differently than they affect the adult brain. Therefore, we aimed to summarize anim
Publikováno v:
Brain, behavior, and immunity. 108
Early-life stress (ELS) may affect brain maturation and neuroimmune interactions and, consequently, the inflammatory response to subsequent environmental factors later in life. Recently, the coexistence of blood-brain barrier (BBB) dysfunction and in
Publikováno v:
Neuroscience. 463:238-253
Clinical studies clearly indicate that early-life stress (ELS) may cause physical and mental health problems later in life. Therefore, the identification of universal biomarkers of ELS-related diseases is very important. The 70-kDa heat shock protein
Autor:
Joanna Kryst, Tomasz Brzostek, Władysław Lasoń, Paweł Kawalec, Andrzej Pilc, Alicja Mikrut Mitoraj
Publikováno v:
Pharmacological Reports
Background Due to unmet clinical needs for efficient drugs with a rapid onset of antidepressant effects, we aimed to evaluate the efficacy of single-dose ketamine in different subgroups of patients with major depression and establish whether repeated
Publikováno v:
Expert opinion on pharmacotherapy. 21(1)
Introduction: In March 2019, intranasal esketamine was approved by the Food and Drug Administration (FDA) for the treatment of treatment-resistant depression (TRD) in adults. This review presents the results of clinical trials underlying the FDA appr